Lamotrigine vs Oxcarbazepine (Oxtellar XR)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Lamotrigine
Marketed by GlaxoSmithKline
NCT01431976 · Phase 3 · completed
This was a small, single-arm, open-label study of 20 participants, with no randomization, blinding, or comparator. The primary clinical endpoint found 7 of 20 participants (35%) seizure free by hyperventilation-EEG at the end of maintenance, but there was no formal between-group comparison.
Reported efficacy
Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Ethosuximide 81/154 | Lamotrigine 43/146 vs Valproic Acid 85/146 (missed)
Result source: NCT00088452
Oxcarbazepine (Oxtellar XR)
Marketed by Supernus Pharmaceuticals
NCT00772603 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and included 366 participants, with seizure frequency as a clinical primary endpoint. The 2,400-mg comparison significantly favored oxcarbazepine, while the 1,200-mg comparison did not, so the primary result was mixed rather than consistently positive.
Reported efficacy
Percent Change in Seizure Rate (one year): Percent Change in Seizure Rate (one year): Oxcarbazepine XR -26.3 percentage of change in seizure rate (range -100 to 344.7) (not_applicable)
Result source: NCT00908349
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lamotrigine | Oxcarbazepine (Oxtellar XR) |
|---|---|---|
| Seizure frequency, % change | 75.4% vs 32.1%+43.3 vs placeboNCT00104416 | —Not reported |
| 50% responder rate | —Not posted · NCT00007670 | 50% vs 34%+16 vs placeboNCT007726031 other result
|
| Seizure freedom | —Not posted · NCT00007670 | —Not reported |
Seizure frequency, % change
- Lamotrigine
- 75.4% vs 32.1%+43.3 vs placeboNCT00104416
- Oxcarbazepine (Oxtellar XR)
- —Not reported
50% responder rate
- Lamotrigine
- —Not posted · NCT00007670
- Oxcarbazepine (Oxtellar XR)
- 50% vs 34%+16 vs placeboNCT00772603
1 other result
- 44% vs 34% NCT00772603
Seizure freedom
- Lamotrigine
- —Not posted · NCT00007670
- Oxcarbazepine (Oxtellar XR)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Lamotrigine: 4 of 4 rows · Oxcarbazepine (Oxtellar XR): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lamotrigine | Oxcarbazepine (Oxtellar XR) |
|---|---|---|
| Dropout rate | 70%a NCT01431976 · Phase 3 · monotherapy show 16 more results0% NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3 — NCT02404168 · Phase 4 · registry result, not featured evidence — NCT01995825 · Phase 4 · registry result, not featured evidence 52.2% NCT01431963 · Phase 3 · registry result, not featured evidence — NCT00516139 · Phase 3 · registry result, not featured evidence 20% NCT00292461 · Phase 3 · registry result, not featured evidence 3.9%Adolescents: LTG NCT00395694 · Phase 3 · registry result, not featured evidence 2%Adults: LTG NCT00395694 · Phase 3 · registry result, not featured evidence —300 mg NCT00355082 · Phase 3 · registry result, not featured evidence 16.8%300 mg NCT00355082 · Phase 3 · registry result, not featured evidence —300 mg NCT00355082 · Phase 3 · registry result, not featured evidence 30.1%250 mg NCT00355082 · Phase 3 · registry result, not featured evidence —250 mg NCT00355082 · Phase 3 · registry result, not featured evidence 13.2% NCT00104416 · Phase 3 · registry result, not featured evidence 0% NCT00789113 · Phase 1/2 · registry result, not featured evidence — NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy | 42.3%2400 mg/dayb NCT00772603 · Phase 3 · Epilepsy · phase 3 show 2 more results32.8%1200 mg/day NCT00772603 · Phase 3 · Epilepsy · phase 3 16.4% NCT00908349 · Phase 3 · monotherapy |
| Discontinued due to AEs | 30%a NCT01431976 · Phase 3 · monotherapy show 16 more results— NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3 — NCT02404168 · Phase 4 · registry result, not featured evidence — NCT01995825 · Phase 4 · registry result, not featured evidence 26.9% NCT01431963 · Phase 3 · registry result, not featured evidence — NCT00516139 · Phase 3 · registry result, not featured evidence 6.7% NCT00292461 · Phase 3 · registry result, not featured evidence 3.9%Adolescents: LTG NCT00395694 · Phase 3 · registry result, not featured evidence 2%Adults: LTG NCT00395694 · Phase 3 · registry result, not featured evidence —300 mg NCT00355082 · Phase 3 · registry result, not featured evidence 3.5%300 mg NCT00355082 · Phase 3 · registry result, not featured evidence —300 mg NCT00355082 · Phase 3 · registry result, not featured evidence 8.8%250 mg NCT00355082 · Phase 3 · registry result, not featured evidence —250 mg NCT00355082 · Phase 3 · registry result, not featured evidence 1.3% NCT00104416 · Phase 3 · registry result, not featured evidence — NCT00789113 · Phase 1/2 · registry result, not featured evidence — NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy | 30.1%2400 mg/dayb NCT00772603 · Phase 3 · Epilepsy · phase 3 show 2 more results14.8%1200 mg/day NCT00772603 · Phase 3 · Epilepsy · phase 3 4.7% NCT00908349 · Phase 3 · monotherapy |
| Serious AEs | 0%a NCT01431976 · Phase 3 · monotherapy show 16 more results1.3% NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3 0% NCT02404168 · Phase 4 · registry result, not featured evidence 0% NCT01995825 · Phase 4 · registry result, not featured evidence 12.3% NCT01431963 · Phase 3 · registry result, not featured evidence 18.2% NCT00516139 · Phase 3 · registry result, not featured evidence 3.3% NCT00292461 · Phase 3 · registry result, not featured evidence 3.9%Adolescents: LTG NCT00395694 · Phase 3 · registry result, not featured evidence 9.8%Adults: LTG NCT00395694 · Phase 3 · registry result, not featured evidence 1.6%300 mg NCT00355082 · Phase 3 · registry result, not featured evidence —300 mg NCT00355082 · Phase 3 · registry result, not featured evidence 2.7%300 mg NCT00355082 · Phase 3 · registry result, not featured evidence —250 mg NCT00355082 · Phase 3 · registry result, not featured evidence 4.5%250 mg NCT00355082 · Phase 3 · registry result, not featured evidence 1.4% NCT00104416 · Phase 3 · registry result, not featured evidence 0% NCT00789113 · Phase 1/2 · registry result, not featured evidence 0% NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy | 8.1%2400 mg/dayb NCT00772603 · Phase 3 · Epilepsy · phase 3 show 2 more results5.7%1200 mg/day NCT00772603 · Phase 3 · Epilepsy · phase 3 8.4% NCT00908349 · Phase 3 · monotherapy |
| Most frequent reported AEs | show 13 more resultsfatigue 8.7% headache 8.1% hostility 6.7% NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3 headache 11.4% dizziness 5.7% blurred vision 2.9% NCT01995825 · Phase 4 · registry result, not featured evidence nasopharyngitis 23.1% headache 21.5% rash 12.3% NCT01431963 · Phase 3 · registry result, not featured evidence dizziness 25.6% balance disorder 20.7% fall 18.2% NCT00516139 · Phase 3 · registry result, not featured evidence diplopia 10% dizziness 6.7% insomnia 6.7% NCT00292461 · Phase 3 · registry result, not featured evidence upper respiratory tract inflammation 29.4% nasopharyngitis 27.5% diarrhoea 21.6% NCT00395694 · Phase 3 · registry result, not featured evidence dizziness 19.6% nasopharyngitis 19.6% contusion 15.7% NCT00395694 · Phase 3 · registry result, not featured evidence 300 mg headache 17.9% dizziness 6% nausea 3.3% NCT00355082 · Phase 3 · registry result, not featured evidence 300 mg headache 25.9% dizziness 10.7% nasalpharyngitis 6.3% NCT00355082 · Phase 3 · registry result, not featured evidence 250 mg headache 27.9% rash 10.8% dizziness 9% NCT00355082 · Phase 3 · registry result, not featured evidence headache 13.9% (placebo 16.2%) vomiting 9.7% (placebo 4.1%) nausea 6.9% (placebo 5.4%) NCT00104416 · Phase 3 · registry result, not featured evidence somnolence 80% dizziness 66.7% headache 60% NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy | 2400 mg/dayb dizziness 40.7% (placebo 14.9%) headache 15.4% (placebo 7.4%) vomiting 15.4% (placebo 9.1%) NCT00772603 · Phase 3 · Epilepsy · phase 3 show 2 more results1200 mg/day dizziness 19.7% (placebo 14.9%) somnolence 11.5% (placebo 9.1%) diplopia 9.8% (placebo 4.1%) NCT00772603 · Phase 3 · Epilepsy · phase 3 |
Notes
- aPopulation comparability has not been reviewed for 16 of these studies.
- bPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lamotrigine
show 2 more results
show 2 more results
show 13 more results
show 1 more result
+ 15 further endpoints in the CSV export.
Oxcarbazepine (Oxtellar XR)
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lamotrigine's landscape · Oxcarbazepine (Oxtellar XR)'s landscape